We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+6.02%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$2.67B
AUM Growth
+$327M
Cap. Flow
+$290M
Cap. Flow %
10.89%
Top 10 Hldgs %
50.32%
Holding
72
New
10
Increased
21
Reduced
14
Closed
11

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$78.7M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$30.8M
3
NRG icon
NRG Energy
NRG
+$23.8M
4
QDEL icon
QuidelOrtho
QDEL
+$23.7M
5
HRTX icon
Heron Therapeutics
HRTX
+$21.3M

Top Sells

Rank Stock Value
1
VST icon
Vistra
VST
+$66.4M
2
HAPN
Happen Inc
HAPN
+$51.8M
3
STNG icon
Scorpio Tankers
STNG
+$48.8M
4
FLR icon
Fluor
FLR
+$34.7M
5
PARR icon
Par Pacific Holdings
PARR
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 35.61%
2 Energy 12.33%
3 Industrials 10.22%
4 Financials 7.91%
5 Utilities 6.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
51
Ardelyx
ARDX
$1.03B
$10.2M 0.38%
+2,500,000
New +$9.75M
MX icon
52
Magnachip Semiconductor
MX
$139M
$8.04M 0.3%
967,867
– –
RSKD icon
53
Riskified
RSKD
$846M
$7.21M 0.27%
+1,610,252
New +$7.42M
MYPS icon
54
PLAYSTUDIOS Inc
MYPS
$72.1M
$6.24M 0.23%
1,961,184
– –
CGEM icon
55
Cullinan Oncology
CGEM
$1.26B
$5.67M 0.21%
626,929
– –
HOWL icon
56
Werewolf Therapeutics
HOWL
$18.6M
$4.14M 0.16%
1,935,357
– –
BCYC
57
Bicycle Therapeutics
BCYC
$284M
$4.13M 0.15%
205,423
– –
TXMD icon
58
TherapeuticsMD
TXMD
$24.1M
$3.6M 0.14%
1,192,191
– –
CNDT icon
59
Conduent
CNDT
$241M
$2.9M 0.11%
+834,660
New +$2.79M
SPRY icon
60
ARS Pharmaceuticals
SPRY
$601M
$2.42M 0.09%
639,203
-2,160,000
-77% -$14.2M
VINC
61
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$358K 0.01%
17,719
– –
ABUS icon
62
Arbutus Biopharma
ABUS
$907M
– –
-3,395,855
Closed -$7.81M
DBRG icon
63
DigitalBridge
DBRG
$2.95B
– –
-795,516
Closed -$11.7M
DMRC icon
64
Digimarc Corp
DMRC
$167M
– –
-375,353
Closed -$11.1M
KPTI icon
65
Karyopharm Therapeutics
KPTI
$46M
– –
-61,280
Closed -$1.65M
HAPN
66
Happen Inc
HAPN
$2.25B
– –
-5,308,472
Closed -$51.8M
PENN icon
67
PENN Entertainment
PENN
$2.57B
– –
-137,428
Closed -$3.3M
RDNT icon
68
RadNet
RDNT
$6.06B
– –
-516,076
Closed -$16.8M
SPCE icon
69
PUT
Virgin Galactic
SPCE
$500M
– –
-30,000
Closed -$2.33M
STNG icon
70
Scorpio Tankers
STNG
$3.81B
– –
-1,033,271
Closed -$48.8M
FREE
71
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
– –
-70,985
Closed -$285K
PNT
72
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-190,000
Closed -$1.72M
1 2
3

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
LAMI
Longview Asset Management (Illinois) Chicago, Illinois $9.56B AUM 25.94% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $9.56B AUM 21.2% 1-Year Est. Return

Rubric Capital Management (New York)'s Q3 2023 Portfolio in Review

As of Q3 2023, Rubric Capital Management (New York) held 72 positions worth $2.67B, up 14% from $2.34B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Rubric Capital Management (New York) deployed $290M of net new capital in Q3 2023, opening 10 new positions and adding to 21 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 1,600,000 shares worth $18.4M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 33% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Vistra, an estimated $66.4M trimmed.

  • Rubric Capital Management (New York)'s largest Q3 2023 buy was Revance Therapeutics, Inc.: 1,600,000 shares worth $18.4M.
  • Rubric Capital Management (New York) added most to Roivant Sciences in Q3 2023, an estimated $78.7M increase.
  • Rubric Capital Management (New York)'s biggest Q3 2023 reduction was Vistra, cutting an estimated $66.4M.
  • Rubric Capital Management (New York) fully exited Happen Inc in Q3 2023, selling an estimated $51.8M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 50% of its $2.67B portfolio in Q3 2023.
  • Rubric Capital Management (New York) opened 10 new positions and closed 11 in Q3 2023.
  • Rubric Capital Management (New York)'s portfolio value rose 14% quarter-over-quarter to $2.67B.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.